Skip to main content

Table 2 Demographic and disease characteristics of study sample

From: Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being

Patients with hATTR Amyloidosis (N = 14)

 

Mean (SD) [Range]

Age (years)

61.5 (14.5) [20–76]

Age at First hATTR Amyloidosis Symptom (years)

50.36 (15.13) [14–73]

Age at Diagnosis (years)

56.29 (16.55) [17–75]

Time Since Diagnosis (years)

5.21 (5.63) [1–21]

 

N (%)

Sex

 Male

8 (57%)

 Female

6 (43%)

Race

 Caucasian/white

13 (93%)

 Asian

1 (7%)

Education

 High school

1 (7%)

 Some college but no degree

1 (7%)

 Associate’s degree or technical certificate

1 (7%)

 Bachelor’s degree

7 (50%)

 Graduate degree

4 (29%)

Marital Status

 Married

10 (71%)

 Divorced

3 (21%)

 Never married

1 (7%)

Region of Residence

 Northeast US

5 (36%)

 South US

5 (36%)

 West US

2 (14%)

 Midwest US

1 (7%)

 Canada

1 (7%)

hATTR Amyloidosis Type

 hATTR amyloidosis with symptoms of both PN and CM

8 (57%)

 hATTR amyloidosis with symptoms of PN only

6 (43%)

Genetic Variant of hATTR Amyloidosis

 V30M

5 (36%)

 T60A

3 (21%)

 Othera

4 (29%)

 Unsure

2 (14%)

Age at Symptom Onset

 Early onset (< 50 years of age)

7 (50%)

 Late onset (≥50 years of age)

7 (50%)

Stage of Ambulatory Disability

 Stage 1: Able to walk unassisted

8 (57%)

 Stage 2: Requires assistance with walking (e.g., walker, cane)

3 (21%)

 Stage 3: Unable to walk (e.g., wheelchair, scooter)

3 (21%)

Impacted Organs/Systemsb

 Nervous

14 (100%)

 Cardiac

8 (57%)

 Gastrointestinal

8 (57%)

 Ocular

4 (29%)

  1. Abbreviations: CM Cardiomyopathy, PN Polyneuropathy, SD Standard deviation, US United States
  2. aOther genetic variants reported by patients: A97S (n = 1), Y114H (n = 1), F64L (n = 1), E54G (n = 1)
  3. bBecause patients could report multiple organ/system involvement, frequency sums to > 100%